Company profile
Alexion Pharmaceuticals, Inc. (subsidiary of AstraZeneca)
Privately held: no public share price (AstraZeneca completed its acquisition of Alexion Pharmaceuticals in July 2021; Alexion now operates as AstraZeneca Rare Disease, a wholly-owned subsidiary, no longer separately listed. Sources: https://clinicaltrials.gov/study/NCT00648739 Entity resolved by asset-pipeline-v2.)
Assets
(1 total)
1Total Assets
1Approved
0Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
| Target & Modality | |||
|---|---|---|---|
Eculizumab(Soliris) | Approved | Complement C5Monoclonal antibody | Chronic Kidney Disease |
Upcoming events
Research
Sign in to access ResearchUnlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Research
Sign in to access ResearchUnlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.